Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 56 of 95, showing 5 Applications out of 474 total, starting on record 276, ending on 280

# Protocol No Study Title Investigator(s) & Site(s)

276.

ECCT/19/05/03   SEARCH
    Supportive Care and Antibiotics for Severe Pneumonia among Hospitalised Children    
Principal Investigator(s)
1. Ambrose Agweyu
Site(s) in Kenya
1. Mama Lucy Kibaki Hospital (Nairobi City county)
2. Kiambu County Referral Hospital (Kiambu county)
3. Machakos County Referral Hospital (Machakos county)
4. Embu County Referral Hospital (Embu county)
5. Naivasha County Hospital (Nakuru county)
6. Bungoma County Referral Hospital (Bung\'oma county)
7. Busia County Referral Hospital (Busia county)
8. Kitale County Referral Hospital (Trans Nzoia county)
9. Kisumu East Hospital (Kisumu county)
10. Kakamega County Referral Hospital, Kenya (Kakamega county)
 
View

277.

ECCT/19/04/05   PHOENIx MDR-TB
    A5300B/I2003B/PHOENIx "Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients"   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Walter Reed Project (Kericho county)
 
View

278.

ECCT/19/06/03   Evaluation of the RTS,S vaccine implementation in Kenya (MVPE)
      An evaluation of the cluster-randomised pilot implementation of the RTS,S/AS01 malaria vaccine through routine health systems in western Kenya         
Principal Investigator(s)
1. Aaron Samuels Samuels
Site(s) in Kenya
1. Bungoma County (Bung\'oma county)
2. Busia County (Busia county)
3. Homa Bay (Homa Bay county)
4. Kakamega County (Kakamega county)
5. Kisumu County (Kisumu county)
6. Migori County (Migori county)
7. Siaya County (Siaya county)
8. Vihiga County (Vihiga county)
 
View

279.

ECCT/19/05/01   A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults
    A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults   
Principal Investigator(s)
1. Omu Anzala
Site(s) in Kenya
KAVI-ICR KNH SITE
 
View

280.

ECCT/19/02/01   DANCE Study
    An Open-Label, Single Arm Study to Evaluate the Week 48 Efficacy and Safety of a Two-Drug Regimen of Dolutegravir/Lamivudine (DTG/3TC) as a Fixed Dose Combination (FDC), in Antiretroviral Therapy (ART)-Naive HIV-1-Infected Adolescents, ≥12 To <18 Years of Age who Weigh at Least 40 Kg.   
Principal Investigator(s)
1. Fredrick Odhiambo Otieno
2. Isaac Tsikhutsu
Site(s) in Kenya
1. Nyanza Reproductive Health Society (Kisumu county)
2. Kenya Medical Research Institute (Kisumu county)
3. Kenya Medical Research Institute, Walter Reed Project (Kericho county)
 
View